Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclarion, Inc. stock logo
ACONW
Aclarion
$0.03
-25.0%
$0.04
$0.01
$0.42
N/AN/A26,240 shs19,189 shs
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
$0.01
$0.00
$0.02
N/AN/A43,690 shs803 shs
Quality Systems, Inc. stock logo
QSII
Quality Systems
$22.35
$0.00
$12.24
$23.73
N/AN/A176,064 shs297,838 shs
SXTPW
60 Degrees Pharmaceuticals
$0.11
$0.09
$0.03
$1.68
N/AN/A6,239 shs7 shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclarion, Inc. stock logo
ACONW
Aclarion
-22.83%-30.23%+13.21%-39.64%-41.41%
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
-10.00%-11.96%-4.71%+39.66%-37.69%
Quality Systems, Inc. stock logo
QSII
Quality Systems
0.00%0.00%0.00%0.00%0.00%
SXTPW
60 Degrees Pharmaceuticals
0.00%+5.00%-4.55%+320.00%+10,499,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclarion, Inc. stock logo
ACONW
Aclarion
N/AN/AN/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Quality Systems, Inc. stock logo
QSII
Quality Systems
N/AN/AN/AN/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclarion, Inc. stock logo
ACONW
Aclarion
N/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/A
Quality Systems, Inc. stock logo
QSII
Quality Systems
N/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/A

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclarion, Inc. stock logo
ACONW
Aclarion
$75.40KN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
Quality Systems, Inc. stock logo
QSII
Quality Systems
N/AN/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
$253.57KN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclarion, Inc. stock logo
ACONW
Aclarion
N/AN/A0.00N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
Quality Systems, Inc. stock logo
QSII
Quality Systems
N/A$0.8625.99N/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclarion, Inc. stock logo
ACONW
Aclarion
N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
Quality Systems, Inc. stock logo
QSII
Quality Systems
N/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aclarion, Inc. stock logo
ACONW
Aclarion
N/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
Quality Systems, Inc. stock logo
QSII
Quality Systems
70.30%
SXTPW
60 Degrees Pharmaceuticals
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aclarion, Inc. stock logo
ACONW
Aclarion
4N/AN/ANot Optionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
4N/AN/ANot Optionable
Quality Systems, Inc. stock logo
QSII
Quality Systems
N/AN/AN/AOptionable
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable

QSII, ATNFW, SXTPW, and ACONW Headlines

No headlines for this company have been tracked by MarketBeat.com

Media Sentiment Over Time

Company Descriptions

Aclarion logo

Aclarion

NASDAQ:ACONW
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
180 Life Sciences logo

180 Life Sciences

NASDAQ:ATNFW
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Quality Systems logo

Quality Systems

NASDAQ:QSII
NextGen Healthcare, Inc. engages in the development and marketing of electronic health records, practice management, revenue cycle management, and interoperability solutions. It offers the core; automation and workflow; analytics, population health, and patient engagement, interoperability; managed services; professional services; and client service and support. The company was founded by Sheldon Razin in 1974 and is headquartered in Atlanta, GA.

60 Degrees Pharmaceuticals

NASDAQ:SXTPW
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.